Sumitomo Pharma and Bukwang Pharmaceutical side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Sumitomo Pharma | Bukwang Pharmaceutical |
|---|---|---|
| Phase 1 | 00% | 00% |
| Phase 2 | Sumitomo Pharma: 4 of its 4 programs at phase 2
| 00% |
| Phase 3 | 00% | Bukwang Pharmaceutical: 1 of its 1 programs at phase 3
|
| Approved, new studies | 00% | 00% |
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma2 readouts · 0 phase 3 | · | · | · | · | · | Sumitomo Pharma, Apr ’27: 1 program whose next study reaches primary completion
| · | Sumitomo Pharma, Jun ’27: 1 program whose next study reaches primary completion
| · | · | · | · |
| Bukwang Pharmaceutical1 readouts · 1 phase 3 | · | · | · | · | · | · | · | · | · | · | · | Bukwang Pharmaceutical, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3
|
Changed in the last 90 days
Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Sumitomo Pharma
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Bukwang Pharmaceutical
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Where they overlap
No condition where two of them both have programs.
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.